Keep Potential Eye Risks With GLP-1 Agonists in Sight

August 2025

Patients will ask if GLP-1 agonists (semaglutide, etc) harm the eyes.

Most GLP-1 agonist labels already warn about diabetic retinopathy.

Now a study links GLP-1 agonists to neovascular (or “wet”) age-related macular degeneration (nAMD)...that can lead to central vision loss.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote